Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
JSJeffrey S HeierAMArshad M KhananiCQCarlos Quezada RuizKBKaren BasuPJPhilip J Ferrone
Roche (Ireland) · Vitreous Retina Macula Consultants of New York · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
665
total citations
- FWCI
- 117.71
- Percentile
- 100%
- References
- 26
Citations per year
Authors
316- JSJeffrey S HeierCorresponding
- AMArshad M Khanani
- CQCarlos Quezada Ruiz
- KBKaren Basu
Roche (Ireland)
- PJPhilip J Ferrone
Vitreous Retina Macula Consultants of New York
Topics & keywords
Topics
Keywords
- Macular degeneration
- Clinical trial
- Phase (matter)
- Phases of clinical research
- Degeneration (medical)
No related works found for this paper.